Cinctive Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Cinctive Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$4.31M	–	372
2025 Q4	$4.31M	Buy	+200,000	New	+$3.88M	0.23%	122
2025 Q1	–	Sell	-69,458	Closed	-$730K	–	317
2024 Q4	$730K	Buy	69,458 +36,446	+110%	+$443K	0.04%	298
2024 Q3	$433K	Buy	+33,012	New	+$503K	0.02%	347
2024 Q2	–	Sell	-21,749	Closed	-$367K	–	400
2024 Q1	$367K	Buy	+21,749	New	+$324K	0.02%	353

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cinctive Capital Management's AVDL Position: Q1 2026 in Review

Cinctive Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 200,000 shares — an estimated $4.31M sold.

Cinctive Capital Management first reported a position in AVDL in Q1 2024 and held it in 4 quarters. The position peaked at $4.31M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Cinctive Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Cinctive Capital Management sold 200,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $4.31M.
Cinctive Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Cinctive Capital Management's Avadel Pharmaceuticals position peaked at $4.31M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.